Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.42 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.33 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 1/20 | 0.32 |
| ▸ | MERTK | Q12866 | 1/20 | 0.32 |
| ▸ | BUB1 | O43683 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521621 | 0.81 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1PIK3R1PIK3CATNK2 | |
| SCHEMBL2790381 | 0.69 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1PIK3R1PIK3CATNK2 | |
| SCHEMBL26819805 | 0.69 | HSP90AA1 (0.50) | HSP90AA1HSP90AB1PIK3R1PIK3CATNK2 | |
| SCHEMBL23416944 | 0.68 | HSP90AA1 (0.55) | HSP90AA1HSP90AB1PIK3R1PIK3CATNK2 | |
| SCHEMBL521646 | 0.68 | JAK2 (0.38) | ALK | |
| SCHEMBL520503 | 0.68 | INSR (0.42) | ALKMET | |
| SCHEMBL22036737 | 0.67 | HSP90AA1 (0.53) | HSP90AA1HSP90AB1PIK3R1PIK3CATNK2 | |
| SCHEMBL423261 | 0.67 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1PIK3R1PIK3CATNK2 | |
| SCHEMBL29797726 | 0.67 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1PIK3R1PIK3CATNK2 | |
| SCHEMBL23416984 | 0.67 | HSP90AA1 (0.54) | HSP90AA1HSP90AB1PIK3R1PIK3CATNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | HSP90AA1 3556/4885HSP90AB1 3666/4885PIK3R1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.